Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients

Share :
Published: 27 Oct 2023
Views: 24
Prof Gerard Zalcman - Université de Paris, Paris, France

Prof Gerard Zalcman speaks to ecancer at the ESMO Congress 2023 to discuss a study aimed at evaluating the feasibility and safety of administering a radiotherapy boost of up to 74 Gy to patients with inoperable stage III non-small cell lung cancer. 

The study was based on the patients' early response to on-treatment FDG-PET/CT at 42 Gy of radiochemotherapy.

Prof Zalcman concludes by discussing the results of the study which found boost at 74 Gy based on interim FDG-PET is feasible and safe during thoracic radio-chemotherapy, without acute or late toxicity.